TABLE 3.
Studies of the efficacy of hepatitis B vaccines in neonates born to HBeAg-positive mothers
| Study | Vaccinea | Dose (μg) | Schedule (mo) | HBIG at birth | No. studied | % HBsAg positive | % Efficacy |
|---|---|---|---|---|---|---|---|
| Beasley et al. (8) | MSD-P | 20 | 0, 1, 6 | Yes | 159 | 2.0–8.6 | 91.4–98.0 |
| Wong et al. (160) | DRC-P | 3 | 0, 1, 2, 6 | Yes | 124 | 9.2–14.4 | 79.3–86.8 |
| Lo et al. (95) | Pasteur | 5 | 0, 1, 2, 12 | Yes | 72 | 8.1–11.4 | 85.5–89.7 |
| Stevens et al. (143) | MSD-P | 20 | 0, 1, 6 | Yes | 158 | 13.9 | |
| MSD-P | 10 | 0, 1, 6 | Yes | 152 | 10.9 | ||
| MSD-R | 5 | 0, 1, 6 | Yes | 351 | 5.4 | ||
| Pongpiat et al. (128) | MSD-R | 5 | 0, 1, 6 | Yes | 20 | 10.0 | 89.2 |
| Lee et al. (87) | SKB | 20 | 0, 1, 2, 12 | Yes | 54 | 7.4 | 91.6 |
| SKB | 10 | 0, 1, 2, 12 | Yes | 56 | 1.8 | 98.0 | |
| SKB | 20 | 0, 1, 6 | Yes | 60 | 3.3 | 96.3 | |
| Poovorawan et al. (131) | SKB | 10 | 0, 1, 2, 12 | Yes | 65 | 1.5 | 97.6 |
| SKB | 10 | 0, 1, 6 | Yes | 60 | 0 | >97 | |
| Beasley et al. (8) | MSD-P | 20 | 0, 1, 6 | No | 40 | 22.5 | 75.0 |
| Wong et al. (160) | DRC-P | 3 | 0, 1, 2, 6 | No | 64 | 24.3 | 65.1 |
| Lo et al. (95) | Pasteur | 5 | 0, 1, 2, 12 | No | 36 | 19.4 | 75.3 |
| Poovorawan et al. (131) | SKB | 10 | 0, 1, 2, 12 | No | 59 | 3.4 | 94.8 |
| SKB | 10 | 0, 1, 6 | No | 59 | 3.4 | 94.8 | |
| Tin (148) | MSD-P | 20 | 0, 1, 2, 6 | No | 113 | 17.7 | 70.4 |
| MSD-P | 10 | 0, 1, 6 | No | 58 | 12.1 | 79.8 | |
| MSD-R | 5 | 0, 1, 6 | No | 60 | 5 | 91.6 | |
| Assateerawatt et al. (2) | MSD-R | 2.5 | 0, 1, 2, 6 | No | 24 | 29 | 66.0 |
| Moulia-Pelat et al. (121) | Pasteur-R | 20 | Mixed | No | 16 | 6.2 | 93 |
a
P, plasma-derived vaccine; R, recombinant vaccine; MSD, Merck vaccine; DRC, Dutch Red Cross; SKB, SmithKline Beecham.